516 related articles for article (PubMed ID: 34691029)
1. The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.
Subtil B; Cambi A; Tauriello DVF; de Vries IJM
Front Immunol; 2021; 12():724883. PubMed ID: 34691029
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids.
Subtil B; Iyer KK; Poel D; Bakkerus L; Gorris MAJ; Escalona JC; van den Dries K; Cambi A; Verheul HMW; de Vries IJM; Tauriello DVF
Front Immunol; 2023; 14():1105244. PubMed ID: 36761758
[TBL] [Abstract][Full Text] [Related]
3. cDC2 plasticity and acquisition of a DC3-like phenotype mediated by IL-6 and PGE2 in a patient-derived colorectal cancer organoids model.
Subtil B; van der Hoorn IAE; Cuenca-Escalona J; Becker AMD; Alvarez-Begue M; Iyer KK; Janssen J; van Oorschot T; Poel D; Gorris MAJ; van den Dries K; Cambi A; Tauriello DVF; de Vries IJM
Eur J Immunol; 2024 Jun; 54(6):e2350891. PubMed ID: 38509863
[TBL] [Abstract][Full Text] [Related]
4. Advances in Modeling the Immune Microenvironment of Colorectal Cancer.
Yoon PS; Del Piccolo N; Shirure VS; Peng Y; Kirane A; Canter RJ; Fields RC; George SC; Gholami S
Front Immunol; 2020; 11():614300. PubMed ID: 33643296
[TBL] [Abstract][Full Text] [Related]
5. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
Kamal Y; Schmit SL; Frost HR; Amos CI
Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.
Nenkov M; Ma Y; Gaßler N; Chen Y
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200820
[TBL] [Abstract][Full Text] [Related]
7. Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive.
O'Toole A; Michielsen AJ; Nolan B; Tosetto M; Sheahan K; Mulcahy HE; Winter DC; Hyland JM; O'Connell PR; Fennelly D; O'Donoghue D; O'Sullivan J; Doherty GA; Ryan EJ
Br J Cancer; 2014 Aug; 111(5):927-32. PubMed ID: 25058349
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell defects in the colorectal cancer.
Legitimo A; Consolini R; Failli A; Orsini G; Spisni R
Hum Vaccin Immunother; 2014; 10(11):3224-35. PubMed ID: 25483675
[TBL] [Abstract][Full Text] [Related]
9. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
11. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.
Tsang YW; Huang CC; Yang KL; Chi MS; Chiang HC; Wang YS; Andocs G; Szasz A; Li WT; Chi KH
BMC Cancer; 2015 Oct; 15():708. PubMed ID: 26472466
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
[TBL] [Abstract][Full Text] [Related]
13. The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance.
Mola S; Pandolfo C; Sica A; Porta C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962159
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
16. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.
Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y
Front Immunol; 2021; 12():667177. PubMed ID: 34025668
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
Xiong Y; Wang Y; Tiruthani K
Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
[TBL] [Abstract][Full Text] [Related]
18. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice.
Xu F; Ye YJ; Liu W; Kong M; He Y; Wang S
Scand J Gastroenterol; 2010 Jun; 45(6):707-13. PubMed ID: 20205622
[TBL] [Abstract][Full Text] [Related]
20. Intestinal multicellular organoids to study colorectal cancer.
Idris M; Alves MM; Hofstra RMW; Mahe MM; Melotte V
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188586. PubMed ID: 34216725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
